Arsenal Capital Partners Acquires Leading Model-Based Drug Development Company Certara

Arsenal Capital Partners, a New York-based private equity firm that invests in middle market healthcare and specialty industrial companies, announced today the acquisition of Certara, provider of model-based drug development and data analytics software and consulting services to the biopharmaceutical research and development market.

Certara provides specialized and integrated solutions which consist of computer-based models supported by scientific consulting services and which span the discovery, pre-clinical and clinical stages of drug development. Certara’s solutions aim to provide clients with significant reductions in the time and expense of bringing new drugs to market by enabling data-driven decisions which lead to more precisely designed studies with less risk of failure and improved subject safety– a benefit in the highly-regulated and increasingly costly research and development environment.

Stephen McLean, a Partner at Arsenal and Co-Head of the firm’s Healthcare Group, said, “We are delighted to invest in this exciting company which is making such an important contribution to improving the productivity of the drug development process. The average cost today of researching and developing a new drug is over $1.5 billion and takes 10-15 years. This is clearly inconsistent with the imperative of reducing the costs of global healthcare and Certara will make a difference.”

Dr. James Rothman, a recipient of the 2013 Nobel Prize in Physiology or Medicine, who evaluated the Certara acquisition in his role in Arsenal Capital Partners’ Healthcare Group, said Arsenal was interested in the acquisition because of Certara's ability to increase both the effectiveness and efficiency of the drug development process. “Model-based drug development is allowing pharmaceutical and biotechnology companies to adopt a more rigorous, quantitative approach to drug development. This allows more informed decisions to be made about which drug candidates to move forward and how to optimize clinical trial designs, which is better for the industry and ultimately for patients,” said Dr. Rothman, who will become a Certara board member.

“Arsenal shares our vision for applying analytics and scientific informatics to facilitate the distribution of pharmaceutical knowledge. After careful assessment, we were impressed with Arsenal’s deep understanding of our mission and our value. We are confident that this is the right match for Certara and one that will benefit both our customers and staff,” said Jim Hopkins, Certara CEO.

Dr. Donald A. Deieso, Operating Partner and Co-Head of Arsenal’s Healthcare Group, commented, “The addition of Certara to our portfolio of companies reinforces our focus on providing the biopharmaceutical industry with solutions which are transformational to their current practices. Technology-driven informatics models will not only result in more cost-effective drug development, but will also serve as the foundation for delivering personalized medicine and clinical care. We plan to build upon Certara’s existing drug development software and consulting services to make the company an even stronger, more versatile partner for its pharmaceutical and biotechnology customers and ultimately execute on Arsenal’s vision of personalized medicine.”

Arsenal’s Certara acquisition follows its 2012 purchase and consolidation into the WIRB-Copernicus Group (WCG) of the Western Institutional Review Board (WIRB), the Copernicus Group IRB, and IRBNet. The acquisition of Certara expands the range of services that its portfolio companies can offer to pharmaceutical and biotechnology firms, and contract research organizations. WCG provides independent IRB services and operates federally-mandated IRB panels.